non-transformed mammary epithelial cell line

Cell Type:
Mammary Epith.
Tissue Origin:
Research Area:
Cancer Research/Cell Biology
Cell Characteristics:

Recommended Media

DMEM:F12 combines the richness of F12 with the higher component concentrations of DMEM. This medium is well suited for clonal density cultures and has been extensively used to demonstrate the effect of various hormones and growth factors on target tissues.

Storage = 2ºC to 8ºC

12-719 = 3.151 g/L glucose, L-glutamine and 15mM HEPES
BE04-687Q = 3.151 g/L glucose and L-glutamine, without HEPES
BE04-687F/U1 = 3.151 g/L glucose and Ultraglutamine I, without HEPES

UltraCULTURE™ Medium is a complete all purpose serum-free medium which supports the growth of a wide variety of both non-adherent and adherent cell lines.
The product is ready-to-use with the simple addition of 5.0 ml of L-glutamine solution (Cat. No. 17-605) per 500 ml.

The medium consists of a DMEM:F-12 base which is supplemented with recombinant human insulin, bovine transferrin and a purified mixture of bovine serum proteins including albumin. The total protein concentration of UltraCULTURE™ Medium is approximately 3 mg/ml. UltraCULTURE™ Medium does not contain L-glutamine.

UltraCULTURE™ Medium may be supplemented with Cryoprotective Medium (Cat. No. 12-132) to cryopreserve cells in a serum-free environment.

Storage = 2ºC to 8ºC

HL-1™ is a Serum-free culture medium containing less than 30 µg protein per ml. Components of HL-1 include known amounts of insulin, a variety of saturated and unsaturated fatty acids and proprietary stabilizing bovine proteins. It contains no bovine serum albumin and does not contain L-glutamine.
HL-1™ will support the serum-free growth of various hybridomas and certain other differentiated cells of lymphoid origin. 

Storage = 2°C to 8°C

Serum-free media developed specifically for growth of mammary epithelial cells.

Available in phenol red-free (basal media = CC3153) and sodium bicarbonate-free (basal media = CC-3152) versions.

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
V T-024 1e6 58% 95% Plasmid (general) 2 µg 100 µl I/II/2b
T T-020 65% 90% Plasmid (general) 2 µg 100 µl I/II/2b
T T-024 65% 90% Plasmid (general) 2 µg 100 µl I/II/2b
SE 96-FF-130 3e4 50-60% good Plasmid (general) 20 µl Shuttle
SE 96-FF-130 2e5 50-60% good Plasmid (general) 400 ng 20 µl Shuttle
SE 96-FF-130 2e5 90% good Plasmid (general) 400 ng 20 µl Shuttle
L X-001 1e6 69% 92% Plasmid (general) 2 µg 100 µl I/II/2b
L X-005 1e6 85% 77% Plasmid (general) 2 µg 100 µl I/II/2b
L T-020 1e6 92% 65% Plasmid (general) 2 µg 100 µl I/II/2b
SE DS-138 2e5 90% 90% Plasmid (general) 20 µl 4D X-Unit


Primary Cells and Media 
Ahmadipour F, Noordin MI, Mohan S, Arya A, Paydar M, Looi CY, Keong YS, Siyamak EN, Fani S, Firoozi M, Yong CL1, Sukari MA, Kamalidehghan B 
Other (2015) 9: 1193-208 
Primary Cells and Media 
Baldari S, Ubertini V, Garufi A, D'Orazi G, Bossi G 
Cell Death Dis. (2015) 6: e1621 
Primary Cells and Media 
Chen L, Du-Cuny L, Moses S, Dumas S, Song Z, Rezaeian AH, Lin HK, Meuillet EJ, Zhang S 
Other (2015) 11(1): e1004021 
Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T, Memeo L, Hibshoosh H, Parsons R 
Cancer Res (2008) 68(6): 1667-74 
Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, Sakanaka C 
Oncogene (2006) 25(31): 4361-9